Millipore Sigma Vibrant Logo

05-23-3831 BQ-123, Sodium Salt - CAS - Calbiochem

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₃₁H₄₁N₆O₇ · Na

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
05-23-3831-1MGCN
Retrieving availability...
Limited Availability
Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA highly potent, selective, and competitive ETA (endothelin) receptor antagonist (Ki = 40 nM for ETA versus Ki = 2.5 μM for ETB).
      Catalogue Number05-23-3831
      Brand Family Calbiochem®
      References
      ReferencesNambi, P., et al. 1996. J. Pharmacol. Exp. Ther. 277, 1567.
      Bax, W.A., and Saxena, P.R. 1994. Trends Pharmacol. Sci. 15, 379.
      Ihara, M., et al. 1991. Biochem. Biophys. Res. Commun. 178, 132.
      Product Information
      ATP CompetitiveN
      FormWhite solid
      FormulationSupplied as a sodium salt. Sold on the basis of peptide content.
      Hill FormulaC₃₁H₄₁N₆O₇ · Na
      Chemical formulaC₃₁H₄₁N₆O₇ · Na
      Hygroscopic Hygroscopic
      ReversibleN
      Sold on the basis of peptide contentY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetETA (endothelin) receptor antagonist
      Primary Target K<sub>i</sub>40 nM for ETA versus 2.5 µM for ETB
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Peptide ContentY
      Peptide SequenceCyclo(D-Asp-Pro-D-Val-Leu-D-Trp, Na)
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      05-23-3831-1MGCN 04055977226812

      Documentation

      BQ-123, Sodium Salt - CAS - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      BQ-123, Sodium Salt - CAS - Calbiochem Certificates of Analysis

      TitleLot Number
      05-23-3831

      References

      Reference overview
      Nambi, P., et al. 1996. J. Pharmacol. Exp. Ther. 277, 1567.
      Bax, W.A., and Saxena, P.R. 1994. Trends Pharmacol. Sci. 15, 379.
      Ihara, M., et al. 1991. Biochem. Biophys. Res. Commun. 178, 132.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision31-May-2011 JSW
      DescriptionA highly potent and selective ETA (endothelin) receptor antagonist (Ki = 40 nM for ETA versus 2.5 µM for ETB).
      FormWhite solid
      FormulationSupplied as a sodium salt. Sold on the basis of peptide content.
      Chemical formulaC₃₁H₄₁N₆O₇ · Na
      Peptide SequenceCyclo(D-Asp-Pro-D-Val-Leu-D-Trp, Na)
      Purity≥95% by HPLC
      SolubilityH₂O (1 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesNambi, P., et al. 1996. J. Pharmacol. Exp. Ther. 277, 1567.
      Bax, W.A., and Saxena, P.R. 1994. Trends Pharmacol. Sci. 15, 379.
      Ihara, M., et al. 1991. Biochem. Biophys. Res. Commun. 178, 132.